Clinician and Patient Reporting of Symptomatic Adverse Events in Cancer Clinical Trials: Using CTCAE and PRO-CTCAE<sup>®</sup> to Provide Two Distinct and Complementary Perspectives.

Minasian, Lori M; O'Mara, Ann; Mitchell, Sandra A

Clinician and Patient Reporting of Symptomatic Adverse Events in Cancer Clinical Trials: Using CTCAE and PRO-CTCAE^® to Provide Two Distinct and Complementary Perspectives.

Minasian, Lori M; O'Mara, Ann; Mitchell, Sandra A.

Afiliación

Minasian LM; Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.
O'Mara A; Consultant, ICF, Fairfax, VA, USA.
Mitchell SA; Consultant to Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.

Patient Relat Outcome Meas ; 13: 249-258, 2022.

Article en En | MEDLINE | ID: mdl-36524232

Palabras clave

PRO-CTCAE; Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events; cancer therapy; patient-reported outcomes; tolerability; toxicity

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Risk_factors_studies Idioma: En Revista: Patient Relat Outcome Meas Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google